{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:49:00Z","timestamp":1777416540937,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[1987,11,1]],"date-time":"1987-11-01T00:00:00Z","timestamp":562723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Intelligence &amp; Clinical Pharmacy"],"published-print":{"date-parts":[[1987,11]]},"abstract":"<jats:p>\n                    Rifampin-induced thrombocytopenia has been recognized as an immunological reaction associated with intermittent high-dose therapy, and rarely seen with daily low-dose regimens. Our patient was a 33-year-old male with Marfan's syndrome who was given rifampin 600 mg\/d po along with intravenous vancomycin for the treatment of Staphylococcus epidermidis endocarditis. His platelet count dropped from a baseline of 519000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    to 4000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    after four doses of rifampin. Petechiae were present on the lower extremities without the presence of other bleeding sites. Rifampin, low-dose aspirin, and dipyridamole were discontinued. His platelet count returned to normal nine days after discontinuation of therapy. With the increasing use of rifampin for the treatment of nontuberculosis infections, clinicians should recognize the possibility of this drug causing such serious immunological reactions as thrombocytopenia, hemolytic anemia, acute renal failure, and shock with daily or intermittent therapy.\n                  <\/jats:p>\n                  <jats:p>Extracto<\/jats:p>\n                  <jats:p>\n                    Rifampin es un agente antibacteriano el cual es utilizado ampliamente en el tratamiento de tuberculosis y de otras infecciones bacterianas. El f\u00e1rmaco puede causar reacciones inmunol\u00f3gicas severas que pueden resultar en trombocitopenia p\u00farpura, anemia hemol\u00edtica, insuficiencia renal, y shock. Estas est\u00e1n usualmente asociadas a dosis altas administradas en una manera intermitente, y la descontinuaci\u00f3n del f\u00e1rmaco usualmente resulta en resoluci\u00f3n de la reacci\u00f3n. Los autores describen el caso de un hombre de 33 a\u00f1os de edad con el S\u00edndrome de Marfan que desarrolla una trombocitopenia severa luego de la administraci\u00f3n de 600 mg diarios de rifampin para el tratamiento de endocarditis causado por Staphylococcus epidermidis. El paciente recibi\u00f3 tambi\u00e9n conjuntamente con rifampin, vancomicina 1 gm iv q 12h, aspirina 600 mg po qd, dipyridamole 25 mg po tid, y propranolol 80 mg po q12h. Cuatro horas luego de la cuarta dosis de rifampin (D\u00eda numero 4) el paciente desarroll\u00f3 petequias en las extremidades inferiores, y el contaje de plaquetas obtenido inmediatamente revel\u00f3 una concentraci\u00f3n de 4000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    , el cual refleja una disminuci\u00f3n significativa en comparaci\u00f3n con el contaje obtenido ocho d\u00edas antes de 519000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    . Tanto rifampin como aspirina y dipyridamole fueron descontinuados. Una marcada trombocitopenia y petequias perduraron por una semana, otras fuentes de sangramiento fueron descartadas y no hubo ning\u00fan cambio significativo en el estado de coagulaci\u00f3n o en el recuento sangu\u00edneo. Las plaquetas regresaron a un nivel normal nueve d\u00edas despu\u00e9s de descontinuado el rifampin. Aunque las plaquetas aumentaron de 11000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    a 36000\/mm\n                    <jats:sup>3<\/jats:sup>\n                    el d\u00eda en que propranolol fue descontinuado, los autores expresan que esta respuesta es muy r\u00e1pida para considerar a \u00e9ste como el agente causante. Aunque no se puede establecer con certeza que la trombocitopenia fuera causada por rifampin o aspirina solamente, o por un efecto sinerg\u00edstico de ambos, rifampin parece ser el agente causante m\u00e1s probable. Es importante reconocer el potencial que posee rifampin para causar reacciones adversas serias como trombocitopenia, anemia hemol\u00edtica, insuficiencia renal aguda, y shock. La terapia con rifampin debe de descontinuarse si alguna de estas ocurren y otras causas no se pueden identificar.\n                  <\/jats:p>\n                  <jats:p>Resume<\/jats:p>\n                  <jats:p>Les thrombocytop\u00e9nies associ\u00e9es avec la rifampicine sont reconnues comme des r\u00e9actions immunologiques rencontr\u00e9es particuli\u00e8rement avec des th\u00e9rapies \u00e0 hautes doses. Le cas d\u00e9crit par les auteurs est celui d'un patient m\u00e2le ag\u00e9 de 33 ans pr\u00e9sentant un syndrome de Marfan \u00e0 qui on a administr\u00e9 600 mg de rifampicine en dose unique quotidienne en combinaison avec vancomycine iv pour le traitement d'une endocardite \u00e0 Staphylococcus epidermidis. Le d\u00e9compte plaquettaire a chut\u00e9 d'une valeur de 519000\/ml \u00e0 4000\/ml seulement quatre heures apr\u00e8s la dose de rifampicine. Des p\u00e9t\u00e9chies \u00e9taient apparentes au niveau des jambes en absence de saignements \u00e0 d'autres sites. Rifampicine, acide ac\u00e9tylsalicylique \u00e0 faible dose, et dipyridamole furent suspendus. Les plaquettes sont revenus a leur niveau normal neuf jours apres l'arr\u00eat de la th\u00e9rapie. Devant l'augmentation de l'utilisation de la rifampicine pour le traitement des infections non-tuberculeuses, les cliniciens devront reconna\u00eetre le potentiel de ce medicament \u00e0 causer des r\u00e9actions immunologiques s\u00e9v\u00e8res telles que thrombocytop\u00e9nie, an\u00e9mie h\u00e9molytique, insuffisance r\u00e9nale et choc.<\/jats:p>","DOI":"10.1177\/106002808702101107","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T12:36:33Z","timestamp":1462970193000},"page":"882-884","source":"Crossref","is-referenced-by-count":3,"title":["Severe Thrombocytopenia Associated with Once-Daily Rifampin Therapy"],"prefix":"10.1177","volume":"21","author":[{"given":"Alice K.","family":"Pau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1987,11,1]]},"reference":[{"key":"bibr1-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.2.115"},{"key":"bibr2-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5803.765"},{"key":"bibr3-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5713.24"},{"key":"bibr4-106002808702101107","first-page":"145","volume":"84","author":"Gomi J","year":"1973","journal-title":"Scand J Respir Dis"},{"key":"bibr5-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5770.343"},{"key":"bibr6-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S440"},{"key":"bibr7-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5916.415"},{"key":"bibr8-106002808702101107","first-page":"160","volume":"84","author":"Sanz FJG","year":"1973","journal-title":"Scand J Respir Dis"},{"key":"bibr9-106002808702101107","first-page":"20","volume":"84","author":"Arioli V","year":"1973","journal-title":"Scand J Respir Dis"},{"key":"bibr10-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.56.651.59"},{"key":"bibr11-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92083-6"},{"key":"bibr12-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92657-2"},{"key":"bibr13-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92343-9"},{"key":"bibr14-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197402000-00008"},{"key":"bibr15-106002808702101107","first-page":"678","volume":"300","author":"Scheinberg IH","year":"1978","journal-title":"N Engl J Med"},{"key":"bibr16-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03320220029016"},{"key":"bibr17-106002808702101107","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S399"}],"container-title":["Drug Intelligence &amp; Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002808702101107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002808702101107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:02:24Z","timestamp":1777374144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002808702101107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1987,11]]}},"alternative-id":["10.1177\/106002808702101107"],"URL":"https:\/\/doi.org\/10.1177\/106002808702101107","relation":{},"ISSN":["0012-6578"],"issn-type":[{"value":"0012-6578","type":"print"}],"subject":[],"published":{"date-parts":[[1987,11]]}}}